CSPC Pharmaceutical Group Ltd. has announced that its Mesalazine Enteric-Coated Tablets, developed by the company, have received drug registration approval from the National Medical Products Administration of the People's Republic of China. This product, which targets inflammatory conditions such as ulcerative colitis and Crohn's disease, has passed the consistency evaluation for the quality and efficacy of generic drugs. The approval marks a significant enhancement to the Group's product portfolio in the immune system therapeutic area. The announcement signifies a key advancement for CSPC Pharmaceutical Group Ltd., as it continues to expand its offerings in the pharmaceutical industry.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。